ஃபைப்ரோபிளாஸ்ட் வளர்ச்சி காரணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃபைப்ரோபிளாஸ்ட் வளர்ச்சி காரணி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃபைப்ரோபிளாஸ்ட் வளர்ச்சி காரணி Today - Breaking & Trending Today

Progression of cardiac hypertrophy in dialysis patients can be retarded by drugs


 E-Mail
Patients with chronic kidney dysfunction frequently develop thickening of the heart muscle, so-called left ventricular hypertrophy. This is particularly pronounced in patients who are in the late stage of renal dysfunction, that is to say those requiring renal replacement therapy such as haemodialysis. The danger of this cardiac hypertrophy lies in the considerable associated increase in risk of acute cardiovascular disease, such as sudden cardiac death, for example. Haemodialysis patients have a number of risk factors for developing this form of cardiac hypertrophy. One of those is elevated levels of the protein Fibroblast Growth Factor 23 (FGF23), and these levels increase as kidney function deteriorates. However, FGF23 can be influenced by drugs in various ways. That is the finding of a recent study led by Katharina Dörr from the Division of Nephrology and Dialysis at MedUni Vienna s Department of Medicine III. ....

Rainer Oberbauer , Vienna Dialysis Center , Meduni Vienna Department Of Medicine , Dialysis Of Meduni Vienna Department Medicine , Division Of Nephrology , Fibroblast Growth Factor , Meduni Vienna , Vienna General Hospital , Divisional Head Rainer , பிரிவு ஆஃப் நெப்ராலஜி , ஃபைப்ரோபிளாஸ்ட் வளர்ச்சி காரணி , வியன்னா ஜநரல் மருத்துவமனை ,

Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study


Research Article
Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study
Winnie Chua,
Affiliation
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
Roles
Writing – original draft,
Writing – review & editing
Affiliations
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom,
Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Roles
Formal analysis,
Validation,
Visualization,
Writing – review & editing
Affiliations
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom,
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, Un ....

Eteläuomen Läi , Black Country , United Kingdom , West Midlands , United Kingdom General , Birmingham Sandwell , Patrick Sulzgruber , German Centre For Heart Research , European Commission , German Centre For Cardiovascular Research , Drug Administration , University Of Birmingham , Leducq Foundation , Research Governance , Health Research Authority , British Heart Foundation , University Of Birmingham Atrial Fibrillation Therapy , Institute Of Cardiovascular Sciences , European Union , National Research Ethics Service Committee Registry , Research Council United Kingdom , German Ministry Of Education , Research Authority , Medizinische Universitat Wien , Creative Commons Attribution License , German Centre ,